ecteinascidin 743 has been researched along with Cardiotoxicity in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coleman, RL; Demetri, GD; Herzog, TJ; Hu, P; Jones, RL; Knoblauch, R; McGowan, T; Monk, BJ; Patel, SR; Schuetze, SM; Shalaby, W; Triantos, S; Van Tine, BA; von Mehren, M | 1 |
| Davidson, D; Doherty, GJ; Hatcher, HM; Wong, HH | 1 |
2 other study(ies) available for ecteinascidin 743 and Cardiotoxicity
| Article | Year |
|---|---|
Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Cardiovascular Diseases; Child; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Doxorubicin; Female; Heart; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Product Surveillance, Postmarketing; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Stroke Volume; Trabectedin; Ventricular Function, Left; Young Adult | 2021 |
Cardiotoxicity with trabectedin in the treatment of advanced soft tissue sarcoma.
Topics: Age Factors; Aged, 80 and over; Antineoplastic Agents, Alkylating; Atrial Fibrillation; Cardiotoxicity; Female; Humans; Male; Myocardial Infarction; Pulmonary Edema; Sarcoma; Trabectedin | 2019 |